Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors

Yoichi Naito, Seigo Nakamura, Nobuko Kawaguchi-Sakita, Takanori Ishida, Takahiro Nakayama, Yutaka Yamamoto, Norikazu Masuda, Koji Matsumoto, Takahiro Kogawa, Kazuki Sudo, Akihiko Shimomura, Catherine Lai, Danjie Zhang, Yuki Iwahori, Dianna Gary, Danh Huynh, Hiroji Iwata

Open source

DOI: 10.1007/s10147-024-02589-x
Published: 2024-09-20
Container: International Journal of Clinical Oncology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10147-024-02589-x,
  title = {Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors},
  author = {Yoichi Naito and Seigo Nakamura and Nobuko Kawaguchi-Sakita and Takanori Ishida and Takahiro Nakayama and Yutaka Yamamoto and Norikazu Masuda and Koji Matsumoto and Takahiro Kogawa and Kazuki Sudo and Akihiko Shimomura and Catherine Lai and Danjie Zhang and Yuki Iwahori and Dianna Gary and Danh Huynh and Hiroji Iwata},
  year = {2024},
  journal = {International Journal of Clinical Oncology},
  doi = {10.1007/s10147-024-02589-x},
  url = {https://doi.org/10.1007/s10147-024-02589-x}
}

RIS

TY  - JOUR
TI  - Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors
AU  - Yoichi Naito
AU  - Seigo Nakamura
AU  - Nobuko Kawaguchi-Sakita
AU  - Takanori Ishida
AU  - Takahiro Nakayama
AU  - Yutaka Yamamoto
AU  - Norikazu Masuda
AU  - Koji Matsumoto
AU  - Takahiro Kogawa
AU  - Kazuki Sudo
AU  - Akihiko Shimomura
AU  - Catherine Lai
AU  - Danjie Zhang
AU  - Yuki Iwahori
AU  - Dianna Gary
AU  - Danh Huynh
AU  - Hiroji Iwata
PY  - 2024
JO  - International Journal of Clinical Oncology
DO  - 10.1007/s10147-024-02589-x
UR  - https://doi.org/10.1007/s10147-024-02589-x
ER  -

APA

Naito, Y., Nakamura, S., Kawaguchi-Sakita, N., Ishida, T., Nakayama, T., Yamamoto, Y., Masuda, N., Matsumoto, K., Kogawa, T., Sudo, K., Shimomura, A., Lai, C., Zhang, D., Iwahori, Y., Gary, D., Huynh, D., & Iwata, H. (2024). Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02589-x

Source records

crossref · retrieved 2026-09-26T15:11:58.575Z